Treatment of Venous Thromboembolism in Real-Life Patients

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Venous Thromboembolism

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03087474

CV185-496

Details and patient eligibility

About

In a population of patients with venous thromboembolism and treated with oral anticoagulants (OAC) in routine clinical practice in Denmark this study will describe patients treated with each OAC

Enrollment: 89,383 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. All patients ≥ 18 years diagnosed with incident VTE at Danish public hospitals from 2006 through 2015
2. First-time (index) VTE will be defined as an in- or out-patient diagnosis of DVT or PE among patients redeeming a prescription for anticoagulant drugs within 30 days after index date

Exclusion criteria

1. In the analyses on type and duration of anticoagulant use, Patients with cancer will be excluded as they typically receive low molecular heparin directly from the hospital and their use of anticoagulants can therefore not be captured by redeemed prescriptions at pharmacies.

Trial design

89,383 participants in 2 patient groups

VKA patients

Description:

Vitamin K antagonist (VKA) patients

Treatment:

Other: Non-Interventional

NOAC patients

Description:

nonvitamin K antagonist oral anticoagulants (NOAC) patients

Treatment:

Other: Non-Interventional